Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN2420 plus somatostatin analogs versus placebo plus somatostatin analogs in adults with acromegaly
NL-OMON59087Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2026
- Modality
- Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acromegaly comparing ALXN2420 + somatostatin analog with Placebo + somatostatin analog (2 arms). Primary endpoint: Percentage change from baseline in serum IGF-1 level at Week 15. Started Apr 2026; status: completed.
02
Drugs
AZP-3813
03
Conditions
acromegaly
Beyond the preview
Go deeper on NL-OMON59087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59087.